Cabergoline, a long-acting dopamine agonist prescribed mainly for elevated prolactin levels, carries a side-effect profile that ranges from the very common and manageable to the rare and serious. Most people taking it for hyperprolactinemia will encounter nothing worse than mild nausea or a passing headache, and these symptoms tend to fade within the first few weeks. The complications that draw the most clinical attention, including heart valve changes, impulse control problems, and psychiatric reactions, are less predictable and depend on dose, duration, and individual vulnerability in ways that matter for anyone starting or already on the drug.
The Everyday Side Effects
Nausea, vomiting, headache, and dizziness are the most frequently reported reactions and are characteristic of all drugs in cabergoline’s class, the ergot-derived dopamine agonists.1PubMed. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation Most people experience these during the first days of treatment or after a dose increase. Taking the tablet at bedtime with food blunts the nausea for many people, and the symptoms typically taper off as the body adjusts to the dopamine stimulation.
Fatigue and constipation also show up regularly in clinical reports, though less often than nausea and dizziness. These are generally mild enough that they do not force anyone to stop the drug. When researchers have compared cabergoline head-to-head with bromocriptine (the older, shorter-acting prolactin-lowering drug), cabergoline consistently comes out ahead on tolerability. In one comparison, side effects were reported by about 12% of cabergoline patients versus 53% of those on bromocriptine.2PubMed. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients A large trial published in the New England Journal of Medicine found that only about 3% of women on cabergoline had to stop because of intolerance, compared with 12% on bromocriptine.3PubMed. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea So while the day-to-day side effects are real, they tend to be milder and shorter-lived than what the alternatives produce.
Blood Pressure Drops
Cabergoline lowers blood pressure as a pharmacological side effect of dopamine stimulation. For most users the drop is modest and symptom-free, but orthostatic hypotension, the dizzy, lightheaded feeling when you stand up quickly, is one of the more noticeable early reactions. Early studies flagged this as the most symptomatic side effect, with an elderly patient in one trial experiencing a clear episode of it after a dose.4PubMed. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
A study of postpartum women given cabergoline to suppress lactation measured the blood pressure effect more precisely. Systolic blood pressure dropped by about 11 mmHg and diastolic by about 8 mmHg at the 20-to-24-hour mark after the dose.5PubMed. Cabergoline for postpartum lactation suppression: Effect on blood pressure and pulse That is enough to cause dizziness or faintness in someone whose baseline pressure is already on the low side, or who is dehydrated, but it is unlikely to cause problems for someone with normal or elevated pressure. The practical takeaway: stand up slowly in the first day or two after taking your dose, and stay hydrated. If you already take blood pressure medication, your prescriber should factor the additive effect in.
Heart Valve Concerns and Monitoring
The side effect that generates the most anxiety, both in patients and among clinicians, is the association between cabergoline and changes to heart valves. This concern originally came from studies of Parkinson’s disease patients, who take cabergoline at dramatically higher doses (sometimes 3 to 6 mg per day) than the doses used for high prolactin (typically 0.5 to 2 mg per week). At Parkinson’s-level dosing, repeated stimulation of serotonin receptors on valve tissue can cause thickening and stiffening called valvulopathy.
For people using lower doses for hyperprolactinemia, the picture is more reassuring. A review in the European Journal of Endocrinology noted that the dose of cabergoline used for prolactin disorders is considerably less than that used in Parkinson’s disease and that low-dose use is not associated with clinically significant valve disease.6European Journal of Endocrinology. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease A service evaluation reviewing screening data reached a similar conclusion, finding that clinically significant valve dysfunction is uncommon and generally only reported in high cumulative-dose groups.7PubMed Central. Screening for valve disease in patients with hyperprolactinaemia disorders prescribed cabergoline: a service evaluation and literature review That said, valve changes are not impossible at lower doses. One case report documented a patient on up to 6 mg per week (a high dose even by prolactin standards) who accumulated a total of 814 mg over the course of treatment and developed mild valvulopathy, which reversed after the drug was stopped.8PubMed Central. Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation
Because of the dose-dependent risk, guidelines from British cardiology and endocrinology societies recommend getting an echocardiogram before starting cabergoline. If you are taking 2 mg per week or less, a follow-up echo at five years is considered sufficient. If you are on more than 2 mg per week, yearly echocardiograms are recommended.9PubMed Central. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology If you have been on cabergoline for years and nobody has ordered an echocardiogram, it is worth bringing up at your next appointment.
Impulse Control and Behavioral Changes
One of the more unsettling side effects of cabergoline is its capacity to alter behavior in ways the person taking it may not immediately recognize. Dopamine agonists are well known for triggering impulse control disorders (ICDs) in Parkinson’s disease patients, but the same phenomenon can appear in people taking much lower prolactin-level doses. Pathological gambling is the most dramatic and best-documented example. In one case, a woman developed compulsive gambling four years into cabergoline treatment, accumulating financial stress and emotional strain. Two weeks after stopping the drug, the gambling behavior resolved completely.10PubMed Central. Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes In an adolescent with a large prolactinoma, pathological gambling emerged after two and a half years on cabergoline and stopped when the dose was lowered.11PubMed Central. Cabergoline Induced Pathological Gambling in an Adolescent with Prolactinoma
Beyond gambling, a pilot study found that hyperprolactinemic patients on dopamine agonists scored higher on measures of attentional impulsiveness than patients not taking the drugs, and that higher doses of cabergoline correlated with greater impulsivity on a decision-making task.12PubMed Central. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study The effect is not universal. A prospective study of macroprolactinoma patients found no statistically significant difference in gambling, hypersexuality, or impulsivity scores between baseline and follow-up during short-term cabergoline treatment.13Neurology India. Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature The picture that emerges is that these changes tend to develop over months to years, are dose-related, and are more likely in some people than others for reasons not yet well understood.
What makes ICDs especially tricky is that the person affected often does not connect the new behavior to the medication. If you or someone close to you notices new patterns around spending, gambling, eating, or sexual behavior after starting cabergoline, that is worth reporting to your prescriber even if the connection seems unlikely.
Psychiatric Reactions
Beyond impulse control, cabergoline can occasionally trigger frank psychiatric symptoms. Psychosis, though rare, has been reported in patients with no prior mental health history. One case involved a patient who developed severe psychotic symptoms after just four weeks on a low dose.14PubMed Central. Cabergoline Induced Psychosis in a Patient with no Previous History of Psychiatric Disorder Another report described psychosis emerging after a dose increase in a man with no psychiatric background, emphasizing that this risk is underrecognized.15PubMed Central. Cabergoline-Induced Psychosis: A Case Report A case of a first-ever manic episode occurring on cabergoline has also been documented, highlighting that susceptible individuals may develop mania, not just psychosis.16PubMed Central. Cabergoline-induced manic episode: case report
The mechanism is straightforward in principle: cabergoline stimulates dopamine receptors in brain pathways involved in reward and perception. Overstimulating those pathways can produce hallucinations, delusions, or mood swings in a small number of people. One complicating factor is cabergoline’s long half-life, which means the drug lingers in the body for days. That is convenient for dosing (most people take it just once or twice a week), but it also means that if a psychiatric side effect develops, it takes longer to wash out than it would with a shorter-acting drug.
Younger Patients and Mental Health
Children and teenagers may be more sensitive to the psychiatric effects. A series of nine pediatric and adolescent prolactinoma patients found that seven out of nine experienced mental or behavioral side effects, and five had neurological symptoms, even at a median dose of only 0.5 mg per week. Most of these improved when the dose was lowered, and none required stopping the drug entirely.17PubMed. Start low, go slowly – mental abnormalities in young prolactinoma patients under cabergoline therapy The title of that paper captures the clinical strategy neatly: start low, go slowly. For younger patients, gradual dose titration and active questioning about mood and behavior changes are particularly important because adolescents may be less likely to spontaneously report subtle psychological shifts.
Fibrotic Complications
As an ergot-derived compound, cabergoline carries a theoretical risk of fibrosis, the abnormal buildup of scar-like tissue in organs. The heart valve issue described earlier is one form of this. Another, much rarer, form is retroperitoneal fibrosis, where fibrous tissue develops behind the abdominal cavity and can compress the ureters, blocking urine flow. A case report described this occurring after only eight months on a low dose of cabergoline. The patient presented with worsening kidney function, and imaging revealed bilateral obstruction requiring ureteric stents. After stopping cabergoline, the fibrosis partially resolved within three months.18Endocrine Abstracts. A case of retroperitoneal fibrosis on low dose Cabergoline This kind of complication is exceedingly rare at low doses, but it underlines why routine blood tests to monitor kidney function are standard practice during treatment.
When Tumor Shrinkage Causes Its Own Problem
For people with very large prolactinomas, especially those that have grown downward into the sphenoid sinus at the base of the skull, cabergoline can be almost too effective. Rapid tumor shrinkage can expose a hole in the skull base that the tumor mass itself had been sealing. The result is a cerebrospinal fluid (CSF) leak, where the fluid that surrounds the brain drains through the nose. In one series, three patients with large, invasive prolactinomas developed CSF leakage four to six weeks after starting cabergoline, a consequence of substantial tumor shrinkage happening faster than the body could repair the dura.19PubMed Central. Cabergoline-induced cerebrospinal fluid fistulae in macroprolactinomas This complication is rare and specific to large, invasive tumors, but patients in that category should be monitored closely for nasal drainage or persistent clear rhinorrhea after starting treatment.20PubMed Central. Cerebrospinal Fluid Leak After Medical Management of Prolactinoma
Stopping Cabergoline and Withdrawal
Most people who stop cabergoline after successful prolactin control do so without incident, but a subset develops what is called dopamine agonist withdrawal syndrome (DAWS). Originally described in Parkinson’s disease patients tapering off higher doses, DAWS involves a cluster of physical and psychological symptoms including anxiety, panic attacks, depression, irritability, fatigue, nausea, sweating, generalized pain, and even drug cravings.21PubMed. Dopamine agonist withdrawal syndrome: implications for patient care The severity is highly variable. Some people have transient symptoms and recover quickly, while others experience a protracted course lasting months or longer.
There is an additional wrinkle: if a patient has developed an impulse control disorder on cabergoline, the standard management is to reduce or stop the drug. This usually resolves the behavioral problem rapidly. But the act of discontinuation can itself trigger DAWS, creating a clinical dilemma where the treatment for one side effect risks provoking another.22PubMed Central. Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes Gradual tapering rather than abrupt cessation is the general approach to minimize this risk.
Pregnancy Safety
Because prolactinomas are most common in women of reproductive age, the question of fetal safety comes up frequently. The evidence here is relatively reassuring. A systematic review covering more than 1,600 pregnancies exposed to cabergoline found that most studies did not show an increased risk of birth defects or miscarriage compared with untreated pregnancies, though overall study quality was low.23PubMed Central. Cabergoline Use and Pregnancy Outcomes: A Systematic Review An earlier study of pregnancies exposed to cabergoline in the first weeks found that spontaneous abortion and major malformation rates were comparable to those in the general population.24PubMed. Pregnancy outcome after cabergoline treatment in early weeks of gestation A 12-year observational study confirmed that fetal exposure through early pregnancy did not increase the risk of miscarriage or malformation.25PubMed. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study
Standard practice is still to discontinue cabergoline once pregnancy is confirmed, since ongoing exposure is unnecessary if the goal is fertility restoration. But accidental exposure in the first weeks before pregnancy is recognized does not appear to be a cause for alarm based on the data available.
Metabolic Effects
High prolactin itself wreaks havoc on metabolism, worsening insulin resistance, lipid profiles, and body composition. Treating the underlying hyperprolactinemia with cabergoline tends to reverse many of these metabolic disturbances, making it hard to separate the drug’s direct metabolic effects from the benefits of normalizing prolactin. That said, there is evidence that cabergoline has independent metabolic effects worth noting.
In prolactinoma patients, five years of cabergoline treatment was associated with significant reductions in markers of metabolic syndrome, including improved lipid profiles, lower fasting insulin, and decreased insulin resistance.26PubMed. Effect of cabergoline on metabolism in prolactinomas A pilot study in obese adults without prolactinomas found that cabergoline improved postprandial glucose and insulin levels compared with placebo, without causing significant weight loss, suggesting the metabolic benefit may be partly independent of prolactin normalization.27PubMed Central. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults A small trial in people with prediabetes found improvements in insulin sensitivity after 16 weeks of twice-weekly cabergoline.28Iranian Journal of Pharmaceutical Research. Does Twice-weekly Cabergoline Improve Anthropometrical and Biochemical Profiles in Prediabetes? A Randomized Double-blind Clinical Trial Pilot Study These findings are preliminary, based on small studies, and do not justify using cabergoline as a metabolic therapy. But they help explain why some patients feel metabolically “better” on the drug beyond what prolactin normalization alone would predict.
Drug Interactions
Cabergoline is metabolized in part by the liver enzyme CYP3A4. Drugs that strongly inhibit this enzyme can significantly raise cabergoline levels in the blood. The best-studied example is clarithromycin, a common antibiotic. In healthy volunteers, co-administration of clarithromycin increased average plasma cabergoline concentrations roughly 2.6-fold. In Parkinson’s disease patients, the increase was about 1.7-fold.29PubMed. Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson’s disease Other potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, and certain HIV medications, would be expected to have a similar effect. If you are prescribed a short course of one of these drugs while on cabergoline, your doctor may need to temporarily adjust the cabergoline dose or monitor you more closely for side effects like dizziness and nausea.
Cabergoline Versus Bromocriptine in Parkinson’s Disease
Most of what has been discussed above concerns the typical hyperprolactinemia patient on low weekly doses. But cabergoline is also used at much higher daily doses as an adjunct in Parkinson’s disease, and the side-effect profile there shifts. A Cochrane review comparing cabergoline to bromocriptine in Parkinson’s patients found that cabergoline produced more involuntary movements (dyskinesia) and more confusion than bromocriptine. Otherwise, the two drugs had comparable dopaminergic side effects, and there was no significant difference in the rate at which patients discontinued either drug.30PubMed Central. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson’s disease The higher rate of confusion at Parkinson’s-level doses is a factor that weighs heavily in older adults, where cognitive side effects can be mistaken for disease progression.
Sleep and Daytime Drowsiness
Dopamine agonists as a class have been associated with sudden-onset daytime sleepiness and “sleep attacks,” which is a meaningful safety concern for anyone who drives. With cabergoline specifically, the data are more reassuring than with some of its relatives. Two polysomnography studies in Parkinson’s patients found no significant increase in daytime sleepiness when cabergoline was added to treatment, and no sleep attacks were observed.31PubMed. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study One of these studies did note that cabergoline may have negative effects on REM sleep, the deep sleep phase involved in dreaming and memory consolidation, despite otherwise improving motor symptoms at night.32PubMed. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson’s disease patients. An ambulatory polysomnographic study Some patients report unusually vivid dreams or disrupted sleep architecture early in treatment, consistent with this REM effect. If you notice significant changes in sleep quality or excessive daytime fatigue, it is worth discussing with your doctor rather than simply attributing it to stress or poor sleep hygiene.
Overdose
Intentional or accidental overdose with cabergoline is exceedingly rare but has been documented. A fatal case involved a 79-year-old woman with Parkinson’s disease who was found confused and jaundiced. Her blood concentration of cabergoline was roughly 100 times above the therapeutic level, and she died two weeks after admission.33PubMed. A fatal overdose of the ergot derivative cabergoline At normal therapeutic doses, the drug has a wide safety margin, but because cabergoline tablets are small and concentrated, accidental ingestion by children or dosing errors in elderly patients with cognitive impairment represent plausible risk scenarios. Keeping the medication in a clearly labeled, child-resistant container is standard good practice.